Christos S Karapetis

Summary

Affiliation: Flinders University
Country: Australia

Publications

  1. ncbi request reprint Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up
    C S Karapetis
    Department of Medical Oncology, Guy s Hospital, London, United Kingdom
    Intern Med J 33:427-35. 2003
  2. ncbi request reprint PET and PLAP in suspected testicular cancer relapse: beware sarcoidosis
    C S Karapetis
    Department of Medical Oncology, Guy's Hospital, London, UK
    Ann Oncol 12:1485-8. 2001
  3. doi request reprint K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
  4. doi request reprint A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas
    Christos S Karapetis
    Department of Medical Oncology, Guy s Hospital, London, UK
    Asia Pac J Clin Oncol 6:298-305. 2010
  5. ncbi request reprint Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy
    Sunita Padman
    Department of Medical Oncology, The Queen Elizabeth Hospital and University of Adelaide, South Australia, Australia
    Acta Oncol 52:1699-706. 2013
  6. ncbi request reprint Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor
    Rajiv Kumar
    Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, Australia
    Clin Colorectal Cancer 13:87-93. 2014
  7. doi request reprint Current opinion on optimal treatment for colorectal cancer
    Timothy J Price
    The Queen Elizabeth Hospital, Adelaide Colorectal Tumour Group and University of Adelaide, Adelaide, South Australia, Australia
    Expert Rev Anticancer Ther 13:597-611. 2013
  8. doi request reprint A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer
    Rajiv Kumar
    Department of Medical Oncology, Flinders Medical Center, Bedford Park, South Australia 5042, Australia
    Cancer 119:722-8. 2013
  9. doi request reprint Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors
    Stephen J Clarke
    Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia
    Crit Rev Oncol Hematol 85:121-35. 2013
  10. doi request reprint Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer
    Muhammad A Khattak
    Department of Medical Oncology, Flinders Medical Centre, Adelaide, South Australia, Australia
    Clin Colorectal Cancer 11:247-54. 2012

Collaborators

Detail Information

Publications12

  1. ncbi request reprint Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: single-centre experience with long-term follow up
    C S Karapetis
    Department of Medical Oncology, Guy s Hospital, London, United Kingdom
    Intern Med J 33:427-35. 2003
    ..The objective of the present study was to evaluate the use of FDG-PET in the setting of advanced GCT, and to determine the influence of FDG-PET on subsequent patient management...
  2. ncbi request reprint PET and PLAP in suspected testicular cancer relapse: beware sarcoidosis
    C S Karapetis
    Department of Medical Oncology, Guy's Hospital, London, UK
    Ann Oncol 12:1485-8. 2001
    ..Sarcoidosis, a condition that has been associated with testicular cancer, should always be considered in the differential diagnosis...
  3. doi request reprint K-ras mutations and benefit from cetuximab in advanced colorectal cancer
    Christos S Karapetis
    Flinders Medical Centre and Flinders University, Adelaide, Australia
    N Engl J Med 359:1757-65. 2008
    ..The mutation status of the K-ras gene in the tumor may affect the response to cetuximab and have treatment-independent prognostic value...
  4. doi request reprint A phase I and II trial of epirubicin, cisplatin, 24-hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas
    Christos S Karapetis
    Department of Medical Oncology, Guy s Hospital, London, UK
    Asia Pac J Clin Oncol 6:298-305. 2010
    ..Epirubicin, cisplatin and continuous infusional 5-fluorouracil (5-FU) (ECF) is a well-established chemotherapy regimen but a continuous chemotherapy infusion is not always feasible or acceptable...
  5. ncbi request reprint Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy
    Sunita Padman
    Department of Medical Oncology, The Queen Elizabeth Hospital and University of Adelaide, South Australia, Australia
    Acta Oncol 52:1699-706. 2013
    ..Conversion chemotherapy has increased the population who are suitable for surgery. Here we assess patterns of care and treatment outcome in liver only metastases in South Australia using the clinical registry for advanced CRC...
  6. ncbi request reprint Colorectal cancer survival: An analysis of patients with metastatic disease synchronous and metachronous with the primary tumor
    Rajiv Kumar
    Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park, Australia
    Clin Colorectal Cancer 13:87-93. 2014
    ..Whether metastatic colorectal cancer (mCRC) that presents synchronously with the primary lesion behaves differently from mCRC that appears metachronously to the primary disease is not clear...
  7. doi request reprint Current opinion on optimal treatment for colorectal cancer
    Timothy J Price
    The Queen Elizabeth Hospital, Adelaide Colorectal Tumour Group and University of Adelaide, Adelaide, South Australia, Australia
    Expert Rev Anticancer Ther 13:597-611. 2013
    ..This article reviews the evidence in support of modern treatments for CRC and the decision-making behind the treatment choices, their benefits and toxicities...
  8. doi request reprint A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer
    Rajiv Kumar
    Department of Medical Oncology, Flinders Medical Center, Bedford Park, South Australia 5042, Australia
    Cancer 119:722-8. 2013
    ..Life expectancy is increasing, and more patients are presenting with cancer at an advanced age (≥80 years). Optimal management for this group of patients has not been well defined...
  9. doi request reprint Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors
    Stephen J Clarke
    Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia
    Crit Rev Oncol Hematol 85:121-35. 2013
    ..In this article, the current concepts of tumour and patient-related predictive factors in CRC management are reviewed...
  10. doi request reprint Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer
    Muhammad A Khattak
    Department of Medical Oncology, Flinders Medical Centre, Adelaide, South Australia, Australia
    Clin Colorectal Cancer 11:247-54. 2012
    ..Colorectal cancer is the third most common cancer in Australia. The median overall survival for metastatic colorectal cancer is nearly 2 years. However, there may be survival differences based on site of metastatic disease...
  11. ncbi request reprint Cetuximab for the treatment of colorectal cancer
    Derek J Jonker
    Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada
    N Engl J Med 357:2040-8. 2007
    ..Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR...